Cerebrolysin Peptide Fraction
Pharmaceutical preparation of low-molecular-weight peptides derived from porcine brain, approved in some countries for dementia and stroke recovery.
Overview
Cerebrolysin is a pharmaceutical preparation of low-molecular-weight peptides and free amino acids derived from purified porcine brain, produced by Ever Neuro Pharma. It is approved as a drug in a number of countries outside the United States for indications that include Alzheimer's disease and stroke recovery.
Although it is frequently grouped with peptide products in catalogs, it is a standardized tissue-derived mixture rather than a single defined peptide. Published clinical trials and meta-analyses exist in dementia and stroke.
Mechanism
The preparation is proposed to act as a mixture of neurotrophic signals: in vitro and animal work has reported neuroprotective, neurotrophic-like, and plasticity-promoting actions, including effects relevant to excitotoxicity and amyloid-related pathology. Because it is a complex mixture, the active constituents and their relative contributions are incompletely characterized.
The assumption that peripherally administered peptides reach the brain in sufficient amounts also remains debated.
Dosing
In published clinical protocols, cerebrolysin is administered by intravenous infusion over multiple sessions across several weeks; amounts and schedules vary by indication and trial. Use outside approved indications is unstandardized.
- Intravenous infusion in published dementia and stroke protocols
- Treatment typically involves repeated sessions over multi-week cycles
- Dosing varies across trials; no universal protocol exists
Expected Effects
- Modest cognitive benefits reported in some Alzheimer's disease trials and meta-analyses
- Improved functional outcomes reported in some post-stroke rehabilitation studies
- Effects across trials are heterogeneous, and large confirmatory trials are limited
Side Effects & Tolerability
In clinical studies the preparation is generally described as well tolerated; occasional dizziness, agitation, or infusion-site reactions have been reported, and hypersensitivity reactions are possible. Per product labeling it is contraindicated in epilepsy and severe renal impairment.
Storage
Pharmaceutical ampoules should be stored according to the product monograph, typically protected from light at controlled temperature, and used before the expiry date.